Goodwin @ JPMorgan

Day 1: The COVID Catalyst

We kicked off the Symposium with industry luminary, Noubar Afeyan, Chairman and Co-Founder of Moderna, which attracted a record 260 viewers. We continued the day with three industry-focused panels, starting with a panel on how COVID-19 boosted innovation across the continuum whether it be devices, therapeutics, diagnostics, supply chain, or the dissemination of needed products and services on a worldwide scale. The second panel addressed how digital health came into the spotlight in 2020 as a result of increased demand for virtual health. We closed the first day with a panel that discussed how the 2020 SPACs revolution will impact the IPO Market for 2021 and beyond.

Panel Titles: 

• Fireside Chat with Noubar Afeyan, Chairman and Co-Founder of Moderna and Founder and CEO of Flagship Pioneering 
• The COVID Catalyst: Driving Innovation Mainstream
• COVID Gives Digital Health a Shot in the Arm
• How the 2020 SPACs Revolution Will Impact the IPO Market for 2021 and Beyond

View the Video:

Goodwin knows that succeeding in the life sciences industry is as much about strategy and execution as it is about research and development. In this highly competitive business, you need more than the best and brightest ideas - you need a legal and strategic partner that understands the challenges of securing funding, safeguarding intellectual property, establishing partnerships, bringing new products to market, opening up new revenue streams, and protecting existing products line.

Goodwin can help. We know the market, the players and the science. With a full service team of highly experienced lawyers resident in key life sciences hubs, Goodwin helps clients find the strategic paths that foster growth and minimize risk across all phases of the corporate life cycle.

Click here to learn more about Gooodwin's Life Sciences practice.